Novamind to Present at H.C. Wainwright 23rd Annual Global Investment Conference
Novamind to Present at H.C. Wainwright 23rd Annual Global Investment Conference
TORONTO, ON / ACCESSWIRE / September 8, 2021 / Novamind Inc. (CSE:NM)(OTC PINK:NVMDF)(FSE:HN2) ("Novamind" or the "Company"), a leading mental health company specialized in psychedelic medicine, is pleased to announce its participation in the H.C. Wainwright 23rd Annual Global Investment Conference ("the Conference"), taking place virtually on September 13-15, 2021.
多倫多，於/ACCESSWIRE/2021年9月8日/諾瓦明公司(CSE：NM)(場外交易市場代碼：NVMDF)(法蘭克福證券交易所市場代碼：HN2)(以下簡稱“諾瓦明”或“公司”)是一家專門從事迷幻藥物的領先精神健康公司，該公司高興地宣佈參加H.C.Wainwright 23研發一年一度的全球投資大會(簡稱“大會”)，實際上是在2021年9月13日至15日舉行的。
Novamind's CEO and Director, Yaron Conforti, will present the Company's business model focused on growing a national network of psychiatry clinics and clinical research sites to rapidly scale access to psychedelic medicine.
Novamind首席執行官兼董事亞倫·康福爾蒂將介紹該公司的商業模式，重點是發展一個全國性的精神病學診所和臨牀研究網站網絡，以迅速擴大迷幻藥物的使用。
The corporate presentation will be available to registered Conference attendees for on-demand viewing beginning at 7:00 AM EST on September 13.
公司演示文稿將在美國東部時間9月13日上午7：00開始向已註冊的與會者提供，供他們點播觀看。
Qualified investors can learn more about the Conference and register to schedule a one-on-one meeting with Novamind's management here.
合格投資者可以在這裏瞭解更多有關大會的信息，並註冊安排與Novamind管理層的一對一會議。
About Novamind
Novamind is a leading mental health company enabling safe access to psychedelic medicine through a network of clinics and clinical research sites. Novamind provides ketamine-assisted psychotherapy and other novel treatments through its network of Cedar Psychiatry clinics and operates Cedar Clinical Research, a contract research organization specialized in clinical trials and evidence-based research for psychedelic medicine. Both Cedar Psychiatry and Cedar Clinical Research are wholly owned subsidiaries of Novamind. For more information on how Novamind is enhancing mental wellness and guiding people through their entire healing journey, visit novamind.ca.
關於諾瓦明 Novamind是一家領先的精神健康公司，通過診所和臨牀研究網站的網絡，使人們能夠安全地獲得迷幻藥物。Novamind通過其Cedar精神病學診所網絡提供氯胺酮輔助的心理治療和其他新療法，並運營Cedar臨牀研究公司，這是一家專門從事迷幻藥物臨牀試驗和循證研究的合同研究組織。錫達精神病學公司和錫達臨牀研究公司都是Novamind公司的全資子公司。有關Novamind如何增強精神健康並指導人們完成整個康復旅程的更多信息，請訪問novamind.ca。
Contact Information
Novamind
Yaron Conforti, CEO and Director
Telephone: +1 (647) 953 9512
聯繫信息諾瓦明Yaron Conforti，首席執行官兼董事電話：+1(647)953 9512
Samantha DeLenardo, VP, Communications
Email: media@novamind.ca
薩曼莎·德萊納多(Samantha DeLenardo)，公關副總裁電子郵件：media@novamind.ca
Bill Mitoulas, Investor Relations
Email: bill@novamind.ca
比爾·米圖拉斯(Bill Mitoulas)，投資者關係部電子郵件：Bill@novamind.ca
Forward-Looking Statements
前瞻性陳述
This news release contains forward-looking statements. All statements other than statements of historical fact included in this release are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Important factors that could cause actual results to differ materially from the Company's expectations including the risks detailed from time to time in the Company's public disclosure. The reader is cautioned not to place undue reliance on any forward-looking information. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in this news release are made as of the date of this news release and the Company will update or revise publicly any of the included forward-looking statements as expressly required by applicable laws.
本新聞稿包含前瞻性陳述。本新聞稿中除歷史事實陳述外的所有陳述均為前瞻性陳述，涉及風險和不確定因素。不能保證這些陳述將被證明是準確的，實際結果和未來事件可能與這些陳述中預期的大不相同。可能導致實際結果與公司預期大不相同的重要因素，包括公司不時公開披露的詳細風險。提醒讀者不要過度依賴任何前瞻性信息。本新聞稿中包含的前瞻性陳述明確受本警告性聲明的限制。本新聞稿中包含的前瞻性陳述是截至本新聞稿發佈之日作出的，公司將根據適用法律的明確要求，公開更新或修改任何包含的前瞻性陳述。
SOURCE: Novamind Inc.
資料來源：諾瓦明公司